Infectious Disease · AntimicrobialRegulatory Approvalcommercialnear-term

FDA Approves Dapsone ANDA213414 by Alembic

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Alembic Pharmaceuticals11 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 12:31:20 PM

Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Alembic's ANDA213414 for Dapsone signifies increased competition in the antimicrobial market. This development could impact pricing and market share for existing Dapsone products, necessitating strategic adjustments from current market players. Regulatory context from FDA (FDA AP — DAPSONE (ORIG)) supports the near-term read. Assessment grounded in 22 ranked evidence items (7 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Alembic's entry on market share and pricing strategies for existing Dapsone products. The strongest clinical anchor is Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P (ClinicalTrials.gov), sponsor/company relevance (novartis). In Infectious Disease · Antimicrobial, 5 regulatory and 6 competitive items passed relevance filtering for Alembic Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease (Merck) — sponsor/company relevance (merck). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DAPSONE (ORIG) (FDA). Entity match (dapsone); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not introduce significant regulatory changes for the industry.

Key Opportunities

Alembic's entry into the Dapsone market may lead to price competition, affecting revenue and market positioning for existing manufacturers.
Portfolio teams should assess the impact of Alembic's entry on market share and pricing strategies for existing Dapsone products.

What Would Change This Assessment

This becomes more urgent if Monitor Alembic's market launch and any subsequent pricing strategies or market responses from competitors.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DAPSONE (ORIG)
FDAhigh relevance
Entity match (dapsone); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
FDA Approves First Single-Dose Generic Treatment for Influenza
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (P
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Can Vitamin D Replacement Correct Chronic Disease Anemia?
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Functional Study to Indentify Genetic Etiology of Rare Diseases - ORIGIN
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Probing Gut-Brain Communication in Parkinson's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in Children and Adolescents Aged 2 through 17 at Increased Risk for Pneumococcal Disease
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Humanexa Signalshigh relevance
Sponsor/company relevance (Merck)
FDA Approves Tioprinin for Treatment of Cystinosis
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Allogeneic T Cell Immunotherapy for Hematologic Malignancies
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves TREGZI for Chronic GVHD in Blood Cancer Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Ginger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of protein palmitoylation in disease pathogenesis and therapeutic innovation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Alembic Pharmaceuticals
Dapsone

Commercial impact

medium

Alembic's entry into the Dapsone market may lead to price competition, affecting revenue and market positioning for existing manufacturers.

Regulatory impact

low

The approval indicates compliance with FDA standards, but does not introduce significant regulatory changes for the industry.

What to watch

Monitor Alembic's market launch and any subsequent pricing strategies or market responses from competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.